Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Etc.); Or Binds Serum Protein, Plasma Protein (e.g., Tpa, Etc.), Or Fibrin Patents (Class 424/145.1)
-
Patent number: 9469688Abstract: Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis.Type: GrantFiled: August 10, 2015Date of Patent: October 18, 2016Assignee: AbbVie Inc.Inventors: Lorenzo Benatuil, Erwin R. Boghaert, Jijie Gu, Maria Harris, Jonathan A. Hickson, Chung-Ming Hsieh, Yuliya Kutskova, Yingchun Li, Zhihong Liu, Susan Morgan-Lappe
-
Patent number: 9463193Abstract: The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by continuous infusion in patients treated by a FOLFIRI regimen or a similar regimen, based on the 5-FU plasmatic concentration measured during the previous 5-FU continuous infusion and on a herein described decision algorithm. The present invention also relates to a method for treating a cancer patient in which the 5-FU dose administered in continuous infusion in each FOLFIRI or similar treatment cycle is optimized using the decision algorithm according to the invention.Type: GrantFiled: September 26, 2008Date of Patent: October 11, 2016Assignees: INSTITUT DE CANCEROLOGIE DE L'OUEST, UNIVERSITE D'ANGERSInventors: Erick Gamelin, Michéle Boisdron-Celle, Alain Morel
-
Patent number: 9416184Abstract: The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.Type: GrantFiled: March 12, 2015Date of Patent: August 16, 2016Assignees: ZymoGenetics, Inc., Merck Serono S/AInventors: Kent Bondensgaard, Roland Beckmann
-
Patent number: 9403909Abstract: The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.Type: GrantFiled: August 10, 2011Date of Patent: August 2, 2016Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Reimi Kawaida, Toshiaki Ohtsuka, Toshinori Agatsuma, Philip Rodley, Sandra Miller, Ulrike Schubert
-
Patent number: 9403882Abstract: Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213. Also provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being sulfated, where the composition is capable of inhibiting sclerostin binding to an LRP. Further provided is a composition comprising a peptide comprising less than about 75 amino acids and/or amino acid analogs including an amino acid or amino acid analog capable of being post-translationally sulfated, where the composition is capable of inhibiting binding of a protein ligand comprising a sulfation site to its binding partner.Type: GrantFiled: June 28, 2011Date of Patent: August 2, 2016Inventors: Joshua Rabbani, James J. Donegan, Xiaofeng Li
-
Patent number: 9388249Abstract: The present invention relates to an isolated antibody against HER1, an isolated antibody against CD147, an isolated antibody against CD73, and an isolated antibody against EpCAM; reagents and compositions including said antibodies; and uses of said reagents, compositions, and antibodies. The present invention also relates to nucleic acids and vectors expressing said antibodies. The invention further relates to transformants comprising said nucleic acids or vectors.Type: GrantFiled: April 30, 2014Date of Patent: July 12, 2016Assignee: AMANO ENZYME INC.Inventors: Atsushi Sugioka, Gene Kurosawa, Mariko Sumitomo, Yoshikazu Kurosawa
-
Patent number: 9364568Abstract: Methods are provided that better describe, and localize the pain generator or suspected pain generator in and around spinal discs in relation to neck or back pain so as to improve the diagnosis of degenerative disc disease. In some embodiments, there are methods for diagnosing a pain generator or a suspected pain generator in a patient suffering from back pain, the methods comprise labeling an inflammatory, vascular, neuronal, and/or metabolic pain marker at a location inside of or adjacent to an intervertebral disc in the patient suffering from back pain to increase an image of the pain marker with an imaging procedure; and imaging the labeled inflammatory, vascular, neuronal, and/or metabolic pain marker in a manner sufficient to diagnose the pain generator or suspected pain generator.Type: GrantFiled: July 15, 2010Date of Patent: June 14, 2016Assignee: Warsaw Orthopedic, Inc.Inventor: Josee Roy
-
Patent number: 9359433Abstract: The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (FGF2) respectively.Type: GrantFiled: November 11, 2015Date of Patent: June 7, 2016Inventor: Andrew B. Bush
-
Patent number: 9353181Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: GrantFiled: June 15, 2012Date of Patent: May 31, 2016Assignee: Janssen Biotech, Inc.Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet
-
Patent number: 9352039Abstract: Compositions, kits, and methods for therapeutic screening, diagnostics, and cancer treatment based on the identification or use of the different states of cancer stem cells, including cancer stem cells in the EMT (epithelial to mesenchymal transition) MET (mesenchymal to epithelial transition), and EMT-MET states are disclosed. In some methods, a subject is treated with one therapeutic that targets EMT cancer stem cells and a second therapeutic that targets MET cancers stem cells. In certain methods, the different states of cancer stem cells are distinguished based on markers CD44+CD24?, EpCam?CD49P+ (for EMT cancers stem cells), ALDH+ and EPCam+CD49r? (for MET cancers stem cells), and CD44+CD24?ALDH+ (for EMT-MET cancer stem cells). In particular methods, micro RNAs are used to transition to one particular cancer stem cell type (e.g., mir-100 for EMT and mir-93 for MET).Type: GrantFiled: February 8, 2013Date of Patent: May 31, 2016Inventors: Suling Liu, Max S. Wicha
-
Patent number: 9345785Abstract: Disclosed are anti-CD70 antibodies and derivatives thereof conjugated to cytotoxic, therapeutic agents, as well as pharmaceutical compositions and kits comprising the antibody- and antibody derivative-drug conjugates. Also disclosed are methods, for the treatment of CD70-expressing a cancer, comprising administering to a subject the disclosed pharmaceutical compositions.Type: GrantFiled: December 10, 2009Date of Patent: May 24, 2016Assignee: Seattle Genetics, Inc.Inventors: Che-Leung Law, Alan F. Wahl, Nathalie Scholler, Linda A. Pestano
-
Patent number: 9326935Abstract: The present invention provides a novel palatable pharmaceutical composition in the form of aqueous solution of atomoxetine. The oral aqueous solution of this invention will significantly reduce the potently bitter taste of atomoxetine, and further avoid swallow issue for young and elderly patients.Type: GrantFiled: December 19, 2013Date of Patent: May 3, 2016Assignee: Eli Lilly and CompanyInventors: Arup Kumar Roy, Matthew Scott Mermey
-
Patent number: 9328165Abstract: The invention provides a method for producing a host cell protein—(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.Type: GrantFiled: August 31, 2015Date of Patent: May 3, 2016Assignee: AbbVie Biotechnology Ltd.Inventors: Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
-
Patent number: 9321836Abstract: The present invention relates to anti-TNF antibodies comprising all of the heavy chain variable CDR regions of SEQ ID NOS: 1, 2 and 3 and/or all of the light chain variable CDR regions of SEQ ID NOS:4, 5 and 6, specific for at least one human tumor necrosis factor alpha (TNF) protein or fragment thereof, as well as nucleic acids encoding such anti-TNF antibodies, complementary nucleic acids, vectors, host cells, production methods and therapeutic methods.Type: GrantFiled: February 18, 2014Date of Patent: April 26, 2016Assignee: Janssen Biotech, Inc.Inventors: George Heavner, David M. Knight, Jill Giles-Komar, Bernard Scallon, David Shealy
-
Patent number: 9309313Abstract: The invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-17 and methods for using this composition to treat IL-17-mediated ocular inflammatory disorders. The invention also discloses devices for delivering this composition to the eye.Type: GrantFiled: January 9, 2009Date of Patent: April 12, 2016Assignee: The Schepens Eye Research Institute, Inc.Inventors: Reza Dana, Sunil Chauhan
-
Patent number: 9284367Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: GrantFiled: June 29, 2012Date of Patent: March 15, 2016Assignee: RANI THERAPEUTICS, LLCInventor: Mir Imran
-
Patent number: 9284364Abstract: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.Type: GrantFiled: November 20, 2013Date of Patent: March 15, 2016Assignee: Amgen Inc.Inventors: Huiquan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou
-
Patent number: 9273142Abstract: The present invention provides glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives and fragments thereof as well as compositions and kits comprising them.Type: GrantFiled: October 10, 2013Date of Patent: March 1, 2016Assignee: SIAMAB THERAPEUTICS, INC.Inventors: Darius Ghaderi, Ana Paula Galvao da Silva
-
Patent number: 9221904Abstract: The present disclosure provides methods for alleviating or delaying the onset of osteoarthritis in a subject in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20, e.g., an anti-IL-20 antibody.Type: GrantFiled: July 18, 2013Date of Patent: December 29, 2015Assignee: National Cheng Kung UniversityInventor: Ming-Shi Chang
-
Patent number: 9221902Abstract: Methods for making a combinatorial antibody library from human germline segments are provided. Also provided are libraries of nucleic acid molecules compiled from germline segments encoding VL chains and libraries of nucleic acid molecules encoding VH chains, and resulting antibody libraries. The libraries are provided as addressable libraries. Methods for screening antibody libraries against a target protein antigen, and the identified or selected antibodies are provided.Type: GrantFiled: November 4, 2009Date of Patent: December 29, 2015Assignee: Fabrus, Inc.Inventors: Vaughn Smider, James Graziano, Helen Hongyuan Mao, Byeong Doo Song, Tyson Chase, Omar Bazirgan
-
Patent number: 9217029Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.Type: GrantFiled: November 14, 2013Date of Patent: December 22, 2015Assignees: UNIVERSITY OF MASSACHUSETTS, E. R. SQUIBB & SONS, L.L.C.Inventors: Donna M. Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
-
Patent number: 9205141Abstract: Immunomodulatory agents, T cell, compositions, methods and systems for treating and/or preventing hypertension and/or a condition associated thereto in an individual.Type: GrantFiled: November 11, 2011Date of Patent: December 8, 2015Assignee: Cardio Vax, LLCInventors: Kuang-Yuh Chyu, Prediman K. Shah
-
Patent number: 9200072Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.Type: GrantFiled: January 18, 2013Date of Patent: December 1, 2015Assignee: GENENTECH INC.Inventors: Yan Wu, Weilan Ye, Jeremy Bryant Burton, Cecilia Chiu
-
Patent number: 9187559Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: GrantFiled: February 20, 2015Date of Patent: November 17, 2015Assignee: AbbVie Biotechnology LtdInventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
-
Patent number: 9180167Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3(CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10), or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: GrantFiled: August 23, 2012Date of Patent: November 10, 2015Assignee: University of Pittsburgh-Of The Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 9181336Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: GrantFiled: March 14, 2013Date of Patent: November 10, 2015Assignee: MEDIMMUNE LIMITEDInventors: Olivia Raeber, Gadi Gazit-Bornstein, Xiao-Dong Yang, Susan Ann Cartlidge, David William Tonge
-
Patent number: 9181345Abstract: The present invention encompasses auto-antibodies associated with autoimmune disorders. The auto-antibodies may be used, for example, in methods of treating patients, methods of diagnosing patients, methods of monitoring disease progression of patients, and methods of prognosing patients.Type: GrantFiled: November 7, 2011Date of Patent: November 10, 2015Assignee: MEDIMMUNE, LLCInventors: Jonathan Zmuda, Christina Strange, Wendy Irene White
-
Patent number: 9164097Abstract: The invention relates to antibodies or fragments thereof specific for insulin-like growth factor binding protein-7 (IGFBP7). A method of raising anti-IGFBP7 single domain antibodies is also disclosed and specific antibody clones are described, along with their binding characteristics. The anti-IGFBP7 antibodies may be useful as diagnostic tools for detecting neoplastic diseases involving tumor angiogenesis, and a variety of other angiogenesis associated diseases.Type: GrantFiled: October 14, 2009Date of Patent: October 20, 2015Assignee: National Research Council of CanadaInventors: Danica Stanimirovic, Abedelnasser Abulrob, Maria Moreno
-
Patent number: 9139646Abstract: Disclosed are methods and materials for inhibiting (e.g., treating or preventing) uveitis in a subject, including treatment refractory uveitis, using anti-IL-1? binding molecules (e.g., IL-1? binding antibodies or binding fragment thereof).Type: GrantFiled: September 17, 2013Date of Patent: September 22, 2015Assignee: XOMA (US) LLCInventors: Alan M. Solinger, Ahmet Gül
-
Patent number: 9139825Abstract: The invention pertains to a natural-variant combinatorial library of fibronectin Type 3 domain (Fn3) polypeptides useful in screening for the presence of one or more polypeptides having a selected binding or enzymatic activity. The library polypeptides include (a) regions A, AB, B, C, CD, D, E, EF, F, and G having wildtype amino acid sequences of a selected native fibronectin Type 3 polypeptide or polypeptides, and (b) loop regions AB, CD, and EF having selected lengths (Bottom Loops). The Fn3 may also have loop regions BC, DE, and FG having wildtype amino acid sequences, having selected lengths, or mutagenized amino acid sequences (Top Loops).Type: GrantFiled: October 27, 2010Date of Patent: September 22, 2015Assignee: NOVARTIS AGInventors: Andreas Loew, Brian Edward Vash
-
Patent number: 9127077Abstract: The present invention relates to polypeptides, nucleic acids and pharmaceutical compositions suitable for use in the treatment of ErbB2 dependent-cancers, in particular of tumors overexpressing ErbB2 or expressing mutated forms of the ErbB2 gene.Type: GrantFiled: September 23, 2010Date of Patent: September 8, 2015Assignee: L'Universite Paris DescartesInventors: Sandrine Bourdoulous, Rym Djerbi-Bouillie
-
Patent number: 9125895Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.Type: GrantFiled: April 1, 2014Date of Patent: September 8, 2015Assignees: Oregon Health & Science University, Vanderbilt UniversityInventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
-
Patent number: 9102723Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.Type: GrantFiled: November 21, 2014Date of Patent: August 11, 2015Assignee: AbbVie Biotechnology LtdInventors: Min M Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
-
Patent number: 9096666Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.Type: GrantFiled: November 21, 2014Date of Patent: August 4, 2015Assignee: AbbVie Biotechnology LtdInventors: Min M Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
-
Patent number: 9090689Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.Type: GrantFiled: April 8, 2015Date of Patent: July 28, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
-
Patent number: 9089524Abstract: The present invention features methods of treating patients with chronic heart failure by administering a neuregulin polypeptide within a dosage range which is both effective and safe.Type: GrantFiled: June 12, 2010Date of Patent: July 28, 2015Assignee: Zensun (Shanghai) Science & Technology LimitedInventor: Mingdong Zhou
-
Patent number: 9085622Abstract: The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.Type: GrantFiled: September 2, 2011Date of Patent: July 21, 2015Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITEDInventors: Neil James Clarke, Kyung Oh Johanson, Zdenka Ludmila Jonak, Alexander H. Taylor, Christopher B. Hopson, Stephen H. Trulli, Zdenka Haskova, Judithann M. Lee, John R. White, Yu Xue
-
Patent number: 9078912Abstract: The present invention relates to a kit for the diagnosis or screening of asthma comprising neuropilin (NRP) gene, and to a method for screening a therapeutic agent for asthma using the same. More precisely, the present invention confirmed that NRP1 expression was increased in asthma patients and by D. pteronissinus extract. Based on the confirmation, the inventors confirmed that NRP1 could be effectively used as a target for the development of a therapeutic agent for asthma since the suppression of NRP1 expression resulted in the decrease of mRNA, protein, enzyme activity, and promoter activity of MMP-9 in relation to asthma.Type: GrantFiled: July 1, 2011Date of Patent: July 14, 2015Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Hyeong Kyu Lee, Kyung Seop Ahn, Yoosik Yoon, Byoung Whui Choi, Ok-Kyoung Kwon, Semi Kim, Hui Seong Kim, Sei Ryang Oh, Ji Eun Yuk, Ha Young Jang
-
Patent number: 9073987Abstract: Methods of treating disorders in which TNF? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.Type: GrantFiled: May 30, 2014Date of Patent: July 7, 2015Assignee: AbbVie Biotechnology Ltd.Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
-
Patent number: 9074004Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: GrantFiled: October 24, 2014Date of Patent: July 7, 2015Assignee: TRUE NORTH THERAPEUTICS, INC.Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Patent number: 9074003Abstract: The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.Type: GrantFiled: January 10, 2014Date of Patent: July 7, 2015Assignee: TRUE NORTH THERAPEUTICS, INC.Inventors: Peter Van Vlasselaer, Graham Parry, Nancy E. Stagliano, Sandip Panicker
-
Patent number: 9073983Abstract: The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.Type: GrantFiled: June 27, 2014Date of Patent: July 7, 2015Assignee: INFLARX GMBHInventors: Renfeng Guo, Niels Cristoph Riedemann, Yan Li, Beifen Shen
-
Patent number: 9067989Abstract: The presently described subject matter is based on the finding that inhibition of eotaxin-2 by polyclonal or monoclonal antibodies, has a significant protective effect in animal models of inflammatory diseases such as rheumatoid arthritis, experimental autoimmune encephalomyelitis (EAE), colitis, diabetes, and atherosclerosis. Thus, provided are pharmaceutical compositions including specific anti-eotaxin 2 antibodies for use alone or in combination with other therapeutic agents in the treatment of inflammatory, autoimmune and cardiovascular diseases. Also provided are specific anti-eotaxin-2 monoclonal antibodies, and methods of treatment utilizing such antibodies.Type: GrantFiled: January 28, 2010Date of Patent: June 30, 2015Assignee: THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTERInventors: Jacob George, Gad Keren
-
Patent number: 9067991Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.Type: GrantFiled: February 27, 2014Date of Patent: June 30, 2015Assignee: Ablynx N.V.Inventor: Els Anna Alice Beirnaert
-
Patent number: 9062105Abstract: The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.Type: GrantFiled: November 7, 2014Date of Patent: June 23, 2015Assignee: Kymab LimitedInventor: Jasper Rupert Clube
-
Patent number: 9061005Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.Type: GrantFiled: March 28, 2012Date of Patent: June 23, 2015Assignee: AbbVie Biotechnology LtdInventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
-
Publication number: 20150147406Abstract: Biodegradable therapeutic agent incorporating microspheres formulated in a high viscosity carrier suitable for intraocular administration to treat an ocular condition.Type: ApplicationFiled: June 6, 2014Publication date: May 28, 2015Inventors: Michael R. Robinson, Wendy M. Blanda, Hui Liu, Scott M. Whitcup, Patrick M. Hughes
-
Publication number: 20150147337Abstract: Crystalline forms of antibodies to human IL-23, such as antibodies to human IL-23p19, are provided, as well as methods of producing such crystalline forms, and uses of such crystalline forms, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. In various embodiments, the anti-hulL-23 antibody crystals, such as anti-hulL-23p19 antibody crystals of the present invention are obtainable by batch crystallization methods, vapor diffusion methods, liquid-liquid diffusion methods, and dialysis. In other aspects, the invention relates to suspensions of the crystalline anti-hulL-23 antibodies of the present invention, including those at higher concentrations and lower viscosities than would be possible with a corresponding non-crystalline solution at the same concentration of antibody. In other embodiments, the anti-huiL-23 antibody crystals of the present invention have increased stability, i.e.Type: ApplicationFiled: June 25, 2013Publication date: May 28, 2015Applicant: Merck Sharp & Dohme Corp.Inventors: Paul Reichert, Winifred W. Prosise, Peter Orth, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi
-
Publication number: 20150139983Abstract: The invention provides pharmaceutical compositions for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several blocking agent(s) of Bone Morphogenic Protein (BMP) signaling. The invention further provides methods of treatment of neuroinflammatory or neurodegenerative diseases comprising administering to a patient in need thereof the pharmaceutical compositions of the invention.Type: ApplicationFiled: June 12, 2013Publication date: May 21, 2015Inventors: Arnon Karni, Yifat Amir Levi, Nataly Urshanski, Karin Bernadet Fainberg
-
Publication number: 20150140008Abstract: A method of treating a disease associated with increased levels of chemokine CXCL17. The method includes administering to a subject in need of such treatment a therapeutically effective amount of a substance that lowers the level of CXCL17 activity. The substance can be a CXCL17 antibody, or an antisense compound targeting CXCL17 such as an antisense oligonucleotide or an siRNA. Also provided are methods of treating tumors with CXCL17 and methods of diagnosing a disease associated with increased levels of CXCL17.Type: ApplicationFiled: May 3, 2013Publication date: May 21, 2015Applicant: The Regents of the University of CaliforniaInventors: Albert Zlotnik, Amanda M. Burkhardt